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http://dxObjective: Simultaneous inhibition of the cardiac equilibrative-p-nitrobenzylthioinosine (NBMPR)–sensi-
tive (es) type of the equilibrative nucleoside transport 1 (ENT1) nucleoside transporter, with NBMPR,
and adenosine deaminase, with erythro-9-[2-hydroxy-3-nonyl]adenine (EHNA), prevents release of myocar-
dial purines and attenuates myocardial stunning and fibrillation in canine models of warm ischemia and re-
perfusion. It is not known whether prolonged administration of hypothermic cardioplegia influences purine
release and EHNA/NBMPR-mediated cardioprotection in acutely ischemic hearts.
Methods: Anesthetized dogs (n¼ 46), which underwent normothermic aortic crossclamping for 20 minutes on-
pump, were divided to determine (1) purine release with induction of intermittent antegrade or continuous retro-
grade hypothermic cardioplegia and reperfusion, (2) the effects of postischemic treatment with 100 mM EHNA
and 25 mMNBMPR on purine release and global functional recovery, and (3) whether a hot shot and reperfusion
with EHNA/NBMPR inhibits purine release and attenuates ventricular dysfunction of ischemic hearts.Myocardial
biopsies and coronary sinus effluents were obtained and analyzed using high-performance liquid chromatography.
Results: Warm ischemia depleted myocardial adenosine triphosphate and elevated purines (ie,
inosine>adenosine) as markers of ischemia. Induction of intermittent antegrade or continuous retrograde hy-
pothermic (4C) cardioplegia releases purines until the heart becomes cold (<20C). During reperfusion, the
levels of hypoxanthine and xanthine (free radical substrates) were>90% of purines in coronary sinus effluent.
Reperfusion with EHNA/NBMPR abolished ventricular dysfunction in acutely ischemic hearts with and without
a hot shot and hypothermic cardioplegic arrest.
Conclusions: Induction of hypothermic cardioplegia releases purines from ischemic hearts until they become
cold, whereas reperfusion induces massive purine release and myocardial stunning. Inhibition of cardiac
es-ENT1 nucleoside transporter abolishes postischemic reperfusion injury in warm and cold cardiac surgery.
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SPatients who present for thrombolytic therapy, percutaneous
coronary interventions, and coronary artery bypass grafting
experience variable degrees of metabolic derangement and
functional and electrophysiologic abnormalities prior to
cardiac surgery. Although resumption of blood flow (reper-
fusion) to ischemic myocardium alleviates oxidative stress
and salvages the myocardium, it promotes vascular damage
and ventricular dysfunction (myocardial stunning).1-4
Reperfusion injury is triggered initially by the production
of oxygen-derived free radicals,2,4,5 whereas activation of
neutrophils6 and inflammatory responses7 play a role in
late consequences of reperfusion injury.
The prolonged intraoperative recovery period makes the
heart more vulnerable to arrhythmias, fibrillation, and
pump failure, and affects adversely the outcome of
cardiac surgery. Developing new modalities that manage
reperfusion injury is a reasonable approach toward car-
dioprotection in different clinical settings of ischemicrdiovascular Surgery c Volume 146, Number 4 961
Abbreviations and Acronyms
ATP ¼ adenosine triphosphate
EHNA ¼ erythro-9-[2-hydroxy-3-nonyl]adenine
es-ENT1 ¼ equilibrative-p-nitrobenzylthioinosine–
sensitive type of the equilibrative
nucleoside transport 1
HPLC ¼ high-performance liquid
chromatography
NBMPR ¼ p-nitrobenzylthioinosine
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Ssyndromes. For the past 3 decades, ischemic precondition-
ing maneuvers applied on naive hearts and normal animals
provided powerful cardioprotective responses, yet they
failed to protect further stunned,8,9 infarcted,10 hypertro-
phied, and failing hearts.11,12 Therefore, well-defined and
specific pharmacologic interventions capable of preventing
ventricular dysfunction or accelerating functional recovery
of stunned, infarcted, hypertrophied, and failing hearts
undergoing cardiac surgery assume significant clinical
relevance.
Previously, we have shown that normothermic global or
regional ischemia promotes purine release, and that it was
associated with sustained ventricular dysfunction and in-
creased the incidents of ventricular fibrillation.2-4,8,9,13-15
Furthermore, we demonstrated that pre- and postischemic
inhibition of the equilibrative-p-nitrobenzylthioinosine
(NBMPR)–sensitive (es) type of the equilibrative
nucleoside transport 1 (ENT1) nucleoside transport with
NBMPR and adenosine deaminase activity with erythro-
9-[2-hydroxy-3-nonyl]adenine (EHNA) blocks release of
purines and attenuates ventricular dysfunction and fibrilla-
tion.2-4,8,9,13-15 The inhibitory effects of EHNA/NBMPR
are site specific and are limited to the ischemic
myocardium.4 Although we have demonstrated the effi-
cacy of EHNA/NBMPR intervention in various models
of warm ischemia and reperfusion, it is not known whether
prolonged infusion of hypothermic cardioplegia affects
purine release from ischemic hearts and subsequently
influences cardioprotection offered by EHNA/NBMPR
treatment.
The goals of the current study are (1) to determine
whether infusion of intermittent antegrade or continuous
retrograde hypothermic cardioplegia into acute ischemic
hearts triggers releases of adenosine triphosphate (ATP) ca-
tabolites, which are known to be markers of ischemia and
substrates for the production of oxygen-derived free radi-
cals on reperfusion; and (2) to determine the role of the
NBMPR-sensitive es-ENT1 nucleoside transporter in reper-
fusion injury in acutely ischemic hearts undergoing either
unprotected warm ischemia and reperfusion or warm ische-
mia followed by prolonged hypothermic cardioplegic arrest
and reperfusion.962 The Journal of Thoracic and Cardiovascular SurgMETHODS
Materials
Biochemical reagents, EHNA, and NBMPR were purchased from
Sigma-Aldrich Chemical Company (St. Louis, Mo).
Animal Model
The following studies conform to the Guide for the Care and Use of
Laboratory Animals published by the US National Institute of Health.16
Forty-six microfilaria-free adult mongrel dogs of either sex, weighing
18 to 26 kg were used in this study. Dogs were anesthetized initially
with 35 mg/kg sodium pentobarbital intravenously (Nembutal; Abbott
Laboratories, Chicago, Ill) and maintained with 10-mg/kg boluses of so-
dium pentobarbital. The surgical procedure and instrumentation were per-
formed as described previously.2 The right phrenic nerve was transected
and the sinoatrial node was crushed, and the heart was paced at rate of
150 bpm. Body and heart temperatures were maintained at 37  1C.
Dogs were heparinized with an intravenous injection with porcine-based
heparin (400 U/kg) as an initial bolus followed by 200 U/kg/hour (El-
kins-Sinn Inc, Cherry Hill, NJ), then placed on cardiopulmonary bypass us-
ing a membrane oxygenator (Medtronic, Minneapolis, Minn). The
extracorporeal circulation was primed with noncross-matched
homologous blood from a bleeder dog, and an aortic cannula and a 2-stage
venous cannula were introduced into the right atrium and the inferior vena
cava, respectively. The azygous vein was occluded and the left ventricle
was vented at the apex. The mean arterial reperfusion pressure was main-
tained at 60 to 65 mm Hg while on bypass. Arterial blood gases, pH, and
hematocrit were determined routinely and maintained at the following
levels: pressure of oxygen, 100-140 mm Hg; pressure of carbon dioxide,
30-40 mm Hg; pH, 7.32 to 7.48; and hematocrit, about 30%.
All dogs underwent 20 minutes of normothermic aortic crossclamping
on-pump, during which a 12F Foley catheter was introduced into the
coronary sinus orifice under direct vision via right atriotomy. Potassium-
based cardioplegic solution containing 25 g/L dextrose, 110 mEq/L Naþ,
162 mEq/L Cl, 1.0 mEq/L Ca2þ, 32 mEq/L Mg2þ, 16 mEq/L Kþ, 0.98
mmol/L procaine, and Tris buffer (pH 7.8) at 4C with an osmolarity of
419 mOsm/L was infused with either an intermittent antegrade (via aortic)
cannula (1000-mL initial bolus plus 500-mL boluses every 20 minutes
thereafter via an aortic cannula) or as a continuous retrograde coronary si-
nus infusion through the Foley catheter for 100 minutes at a maximal pres-
sure of 40 mm Hg (20-25 mL/minute). Antegrade cardioplegia was
collected from the coronary sinus whereas the retrograde cardioplegic so-
lution washout was collected via an aortic cannula.
Dogswere divided into 3 experimental protocols as described in FigureE1.
The first protocol was established to determine whether infusion of intermit-
tent antegrade (n¼ 7dogs) or continuous retrograde (n¼ 7 dogs) hypothermic
cardioplegia, following 20 minutes of warm aortic crossclamping, promotes
the release of myocardial purines from ischemic hearts. In these experiments,
the infused cardioplegic solution was collected from the coronary sinus
cannula in the intermittent antegrade group or from the aortic root in the con-
tinuous retrograde group. Topical cooling was used to protect the right ventri-
cle. Transmural myocardial biopsies were collected at baseline, at the end of
normothermic aortic crossclamping, during 100 minutes of infusion of hypo-
thermic cardioplegia, and during 60 minutes of reperfusion.
The second protocol was established to determine the effects of post-
ischemic administration of EHNA/NBMPR on myocardial purines and
recovery of ventricular performance without a period of hypothermic
cardioplegic arrest. Hearts were subjected to 20 minutes of warm aortic
crossclamping followed by reperfusion with warm blood containing the
vehicle solution (n ¼ 8) or the vehicle solution with 25 mM NBMPR and
100 mM EHNA (n ¼ 8). A bolus of 1000 mL of the vehicle or the vehicle
solution containing 100 mM EHNA and 25 mM NBMPR was infused into
the pump 5 minutes prior to reperfusion. Myocardial biopsies were ob-
tained at baseline, during cold cardioplegic arrest, and during
reperfusion.ery c October 2013
TABLE 1. Effects of intermittent antegrade or continuous coronary sinus retrograde hypothermic cardioplegia on myocardial purine levels in
acutely ischemic hearts
Purine Preischemia Ischemia, 20 min
Hypothermic cardioplegia Reperfusion
10 min 55 min 85 min 99 min 30 min 60 min
ATP-AC 35.7  3.7 26.0  2.0* 31.0  1.6 26.2  2.7 28.6  3.2 28.5  2.3 22.2  1.2* 21.6  2.6*
ATP-RCSC 27.0  2.4 21.3  1.2* 27.3  2.7 27.1  4.0 27.3  3.1 25.4  2.6 22.6  2.6* 21.4  2.1*
INO-AC 0.1  0.1 7.8  1.0* 8.3  0.9* 7.6  1.0* 9.2  1.9* 7.2  1.2* 0.2  0.1 0.3  0.1
INO-RCSC 0.1  0.1 6.7  1.4* 9.9  1.4* 9.8  1.4* 8.7  1.0* 8.5  1.6* 0.1  0.1 0.1  0.1
TDP-AC 1.2  0.3 12.0  1.4* 11.9  1.1* 10.5  1.0* 11.3  2.3* 10.5  1.4* 1.3  0.1 1.2  0.5
TDP-RCSC 1.4  0.5 10.1  1.1* 13.8  1.5* 13.1  1.9* 12.0  1.2* 11.6  2.3* 1.3  0.1 1.7  0.3
Purine levels are presented as moles per milligram protein, mean standard error of the mean. P¼ not significant, 2-way analysis of variance. ATP, Adenosine triphosphate; AC,
antegrade cardioplegia; RCSC, retrograde coronary sinus cardioplegia; INO, inosine; TDP, total diffusible purines (adenosine þ inosine þ hypoxanthine þ xanthine). *P<.05
versus corresponding preischemic levels (n ¼ 7, each group).
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and reperfusion with EHNA/NBMPR on myocardial purine release and re-
covery of ventricular performance in a model of 20 minutes of normother-
mic aortic crossclamping, continuous infusion of retrograde coronary sinus
cardioplegia, and reperfusion. Ischemic hearts were infused with 500 mL
hot shot cardioplegic solution (37C) with either the vehicle solution
(n¼ 8) or vehicle solution containing 100 mM EHNA and 25 mMNBMPR
(n ¼ 8) before switching to continuous infusion of hypothermic (4C) car-
dioplegic solution with a maximal pressure of 40 mm Hg (20-25 mL/min-
ute). The rationale of using a hot shot of cardioplegic solution as a mean for
drug delivery is that progressive cooling induces a phase transition in cel-
lular membrane phospholipids in such away that they become rigid and im-
permeable to solutes and solutions.17 On the other hand, rapid cooling of
beating hearts could be detrimental by triggering intracellular calcium
overload that ultimately leads to myocardial contracture (stone hearts).18
Myocardial core temperature reached 16 to 18Cwithin 2 to 4 minutes dur-
ing infusion of cold cardioplegia. At the end of 20 minutes of unprotected
ischemia and 100 minutes of cardioplegic arrest, the right atrium was
closed via suture. Reperfusion was initiated by releasing the crossclamp
and allowing the heart to be reperfused with warm blood with or without
EHNA/NBMPR for 60 minutes. Coronary sinus effluent during the first
10 seconds of reperfusion was collected in a 20-mL vial containing 0.1
mL of a stopping solution of EHNA/NBMPR, then was frozen immediately
in liquid nitrogen and kept at 80C for later extraction and high-
performance liquid chromatography (HPLC) analysis. Functional mea-
surements were obtained at baseline, and at 30 minutes and 60 minutes
of reperfusion. Myocardial biopsies were obtained at baseline, the end of
normothermic aortic crossclamping, during administration of hypothermic
cardioplegia, and during reperfusion.
Assessment of Left Ventricular Performance
The left ventricular performance was assessed, off bypass pump,
from the relationship between stroke work and end diastolic dimension
as a sensitive and load-independent index of contractility using pulse
transit sonomicrometry (Triton Technology, San Diego, Calif) and
Millar pressure transducers (Millar Instruments, Houton, Tex) as de-
scribed previously.2 One pair of lead titonate zyrconate-piezoelectric
hemispheric crystals was sutured to the anterior and posterior of the epi-
cardial surface of the left ventricle wall in the minor axis (40-60 mm).
Analog data were digitized at 200 Hz and stored on a personal computer
hard disk and analyzed by interactive Crunch software developed in our
laboratory. Data acquisition was performed at varying preloads via
venous drainage creating diminishing cardiac work loops.
Assessment of Adenine Nucleotide Pool Metabolism
Transmural Serial Tru-Cut needle (Cardinal Health, Dublin, Ohio)
biopsy specimens (5-10 mg) were obtained at baseline, at the end ofThe Journal of Thoracic and Cawarm ischemia, during hypothermic arrest, and during reperfusion.
Each biopsy was frozen immediately in liquid nitrogen (196C)
and later extracted, analyzed, and quantified using HPLC (data are re-
ported as nanomoles per milligram protein).2
Statistical Analysis
Data are presented as mean  standard error of the mean. Sequential
measurements were compared using repeated-measures analysis of vari-
ance and Tukey post hoc tests using SAS (version 6.02; Statistical Analysis
System Institute, Cary, NC). Differences were considered significant if the
probability value for comparison of least squares means was<.05.RESULTS
Effects of Infusion of Intermittent Antegrade or
Continuous Coronary Sinus Retrograde
Hypothermic Cardioplegia on Levels of Myocardial
Purines and Their Release From Acutely Ischemic
Hearts
Twenty minutes of on-pump normothermic aortic cross-
clamping depleted myocardial ATP by about 20% to
35% and resulted in a concomitant accumulation of mainly
myocardial inosine (Table 1). Induction of either intermit-
tent antegrade or continuous coronary sinus hypothermic
cardioplegia was associated with early (1-4 minutes) release
of inosine, hypoxanthine, and xanthine, all of which are
known to be sensitive markers of ischemia. Purine release
was abolished when myocardial temperature reached the
cooling range (16-18C) within 1 to 4 minutes (Figure 1,
A and B, and Figure E2, A). This observation was not
only noted with the initial induction of antegrade cardiople-
gia (1000 mL), but also with each subsequent bolus (500
mL) of intermittent antegrade cardioplegia every 20 min-
utes. On the other hand, induction of continuous coronary
sinus cardioplegia was associated with release of purines
into blood effluent collected from the aortic cannula within
1 to 4 minutes of induction of cardioplegia. Purine release
ceased when myocardial temperature reached<20C (base-
line levels) (Figure E2, B). Reperfusion with warm, oxygen-
ated blood robustly released and converted the remaining
purines in the ischemic myocardium to hypoxanthine and
xanthine (Figure 1, A and B, and Table 2).rdiovascular Surgery c Volume 146, Number 4 963
FIGURE 1. Effects of intermittent antegrade or continuous retrograde coronary sinus hypothermic cardioplegia on the levels of myocardial purines as
markers of ischemia of the left ventricle in acutely ischemic hearts. All hearts were subjected to 20 minutes of warm aortic crossclamping on-pump followed
100 minutes of hypothermic cardioplegic arrest and 60 minutes of reperfusion via antegrade or retrograde routes. The P value was not significant among
groups using analysis of variance. *P<.05 versus baseline levels (n ¼ 7). A, Effects of intermittent antegrade or continuous retrograde coronary sinus hy-
pothermic cardioplegia on myocardial inosine levels of the left ventricle in acutely ischemic hearts. B, Effects of intermittent antegrade or continuous ret-
rograde coronary sinus hypothermic cardioplegia on myocardial total diffusible purine (adenosine + inosine + hypoxanthine + xanthine) levels of the left
ventricle in acutely ischemic hearts. TDP, Total diffusible purines.
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NBMPR on the Levels of Myocardial Purines and
Left Ventricular Performance in Acutely Ischemic
Hearts Without Cold Cardioplegic Arrest
The efficacy of postischemic administration of EHNA/
NBMPRwas previously reported8 in the same canine model
and results were used here for comparison. Unprotected
aortic crossclamping caused about 25% to 35% depletion
of myocardial ATP with a concomitant accumulation of
mainly inosine (Table 3). Reperfusion was initiated by964 The Journal of Thoracic and Cardiovascular Surgallowing the heart to be reperfused with warm blood perfu-
sion containing either the vehicle solution or 100 mM
EHNA and 25 mM NBMPR. In the control group, ventricu-
lar performance was depressed by about 50% compared
with baseline function. The slope of the relationship
between stroke work/end diastolic length declined signifi-
cantly to 40.1  6 dyne/cm2$103 and 51.3  3
dyne/cm2$103 at 30 minutes and 60 minutes of reperfusion,
respectively (P<.05 vs baseline function, 103.5  4 dyne/
cm2$103; Table 3). A complete recovery of ventricularery c October 2013
TABLE 2. Purine release at the induction of intermittent antegrade or continuous retrograde hypothermic cardioplegia in acutely ischemic hearts
and reperfusion
Metabolites
Percent of total diffusible purines
Antegrade Retrograde
Induction of cardioplegia Induction of reperfusion Induction of cardioplegia Induction of reperfusion
Adenosine 1.30  0.6 0.31  0.2 0.07  0.1 0.73  0.6
Inosine 17.12  7.3* 2.17  0.3* 11.66  6.1* 2.18  1.3*
Hypoxanthine 53.38  8.6* 49.50  8.2* 54.97  13* 50.84  8.5*
Xanthine 19.94  8.1* 44.03  7.4* 29.35  10* 41.00  6.4*
Baseline levels of purines in plasma of arterial and venous blood from the coronary sinus were below detection levels. On-pump canine hearts were subjected to 20 minutes of
normothermic aortic crossclamping followed by induction of either antegrade or retrograde hypothermic cardioplegia. The initial coronary sinus effluents were collected within
the first 10 seconds into a vial containing a stopping solution (erythro-9-[2-hydroxy-3-nonyl] adenine/p-nitro-benzylthioinosine), then were frozen, extracted, and analyzed by
high-performance liquid chromatography. Results are presented as a percentage of content in milliliters of collected plasma in each study, and reflect the release and conversion of
myocardial adenine nucleosides to hypoxanthine and xanthine. *P<.05 versus adenosine levels (n ¼ 7, each group).
Abd-Elfattah et al Evolving Technology/Basic Sciencefunction was observed in the group that was reperfused with
warm blood containing EHNA/NBMPR. The slopes of
stroke work/end diastolic length relationship in the latter
group reached 108.2  6 dyne/cm2$103 and 93.7  5
dyne/cm2$103 at 30 minutes and 60 minutes of reperfusion,
respectively (P-value not significant vs baseline function,
101$8  4 dyne/cm2$103; Table 3).
Effects of a Hot Shot and Reperfusion of
EHNA/NBMPR on Cardiac Metabolism and
Function in Acutely Ischemic Hearts Undergoing
Retrograde Hypothermic Cardioplegic Arrest and
Reperfusion
In this experiment, acutely ischemic hearts were infused
with a warm cardioplegic solution (hot shot), containing ei-
ther the vehicle solution or EHNA/NBMPR, via the coro-
nary sinus prior to switching to retrograde coronary sinus
cold cardioplegia. Figure 2 depicts the effects of the coro-
nary sinus shot and reperfusion with EHNA/NBMPR beforeTABLE 3. Effects of postischemic reperfusion with EHNA/NBMPR on lef
hearts without hypothermic cardioplegic arrest
Parameters Baseline Ischemia, 20 min
LV performance
Control group (n ¼ 8) 103.5  4 —
EHNA/NBMPR group 101.8  4
Adenosine triphosphate
Control group 24.2  2 18.2  2*
EHNA/NBMPR group 27.3  2 17.5  3*
Adenosine
Control group 0.10  0.1 1.90  0.4*
EHNA/NBMPR group 0.10  0.1 1.75  0.2*
Inosine
Control group 0.10  0.1 9.80  0.3*
EHNA/NBMPR group 0.10  0.1 7.40  0.4*
Results are presented in nanomoles per milligram protein as mean  standard error of the
performance is presented as slop the relationship between strokework/end diastolic length m
deaminase inhibitor); NBMPR, p-nitro-benzylthioinosine (a specific blocker of the es-ENT
versus control group.
The Journal of Thoracic and Caand after continuous retrograde coronary sinus hypothermic
cardioplegia onmyocardial ATP, adenosine, inosine, and to-
tal diffusible purines. The effects of hot shot and reperfu-
sion with EHNA/NBMPR before and after continuous
retrograde coronary sinus hypothermic cardioplegia, re-
spectively, on myocardial ATP in acutely ischemic are
shown in Figure 2, A. Warm aortic crossclamping caused
similar depletion of myocardial ATP in the control and
drug-treated groups (P < .05 vs baseline). Myocardial
ATP levels were higher during cardioplegic arrest compared
with ATP levels at the end of warm ischemia and after reper-
fusion. The reasons for these differences are not known;
however, they could be related to the fact that myocardial
biopsies obtained during cardioplegic arrest had less red
blood cell contaminant, thus reducing protein values in
those particular biopsies on which ATP levels are normal-
ized. The levels of myocardial adenosine (Figure 2, B)
and inosine (Figure 2, C) as well as total diffusible purines
(Figure 2, D) increased significantly during warm ischemiat ventricular performance and purine metabolism in acutely ischemic
Reperfusion
30 min 60 min 90 min 120 min
40.1  6* 51.3  3* 60.8  5* 59.8  3*
108.2  6y 93.7  5y 93.5  6y 95.4  4y
17.6  7* 22.0  2* 18.1  3* 17.9  2*
17.2  2* 17.1  6* 16.3  2* 16.9  2*
0.20  0.1 0.10  0.1 0.10  0.1 0.10  0.1
0.49  0.2 0.25  0.1 0.26  0.1 0.2  0.1
1.00  0.2* 0.14  0.1 0.10  0.1 0.10  0.1
3.60  0.3*,y 1.43  0.1*,y 0.10  0.1 0.10  0.1
mean (n ¼ 8 each group), analyzed by 2-way analysis of variance. Left ventricular
easured in dyne/cm2$103. EHNA, Erythro-9-[2-hydroxy-3-nonyl] adenine (adenosine
1 nucleoside transporter); LV, left ventricle. *P<.05 versus baseline values. yP<.05
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FIGURE 2. Effects of a coronary sinus hot shot and reperfusion with EHNA/NBMPR before and after continuous retrograde coronary sinus hypothermic
cardioplegia on myocardial ATP pool metabolism of the left ventricle in acutely ischemic hearts. All hearts were subjected to 20 minutes of warm aortic
crossclamping on-pump, a hot shot with or without EHNA/NBMPR, followed 100 minutes of retrograde hypothermic cardioplegic arrest and 60 minutes of
reperfusion with or without inhibitors. TheP valuewas not significant among groups using analysis of variance. *P<.05 versus baseline (n¼ 8, each group).
yP<.05 between groups (n ¼ 8). A, Effects of a coronary sinus hot shot and reperfusion with EHNA/NBMPR before and after continuous retrograde cor-
onary sinus hypothermic cardioplegia onmyocardial ATP of the left ventricle in acutely ischemic hearts. B, Effects of a hot shot and reperfusionwith EHNA/
NBMPR before and after continuous retrograde coronary sinus hypothermic cardioplegia on myocardial adenosine of the left ventricle in acutely ischemic
hearts. C, Effects of a hot shot and reperfusion with EHNA/NBMPR, before and after continuous retrograde coronary sinus hypothermic cardioplegia, on
myocardial inosine of the left ventricle in acutely ischemic hearts. D, Effects of a hot shot and reperfusion with EHNA/NBMPR before and after continuous
retrograde coronary sinus hypothermic cardioplegia on myocardial total diffusible purines (adenosine þ inosine þ hypoxanthine þ xanthine) of the left
ventricle in acutely ischemic hearts. ATP, Adenosine triphosphate; EHNA, erythro-9-[2-hydroxy-3-nonyl] adenine; NBMPR, p-nitro-benzylthioinosine;
TDP, total diffusible purines.
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grade cardioplegia. Reperfusion triggered a massive loss
of myocardial adenosine, inosine, and total diffusible pu-
rines in the control group, reflecting their release. Signifi-
cant levels of adenosine, inosine, and total diffusible
purines remained in hearts treated with EHNA/NBMPR
as a hot shot and during reperfusion (P< .05 vs control;
Figure 2, A and B).
Twenty minutes of aortic crossclamping depleted myo-
cardial ATP and accumulated more inosine than adenosine
in the right ventricle, similar to that of the left ventricle
(Figure E3, A-D). Infusion of continuous retrograde cardio-
plegia retained myocardial purines in the right ventricle af-
ter hot shot with or without EHNA/NBMPR. Reperfusion966 The Journal of Thoracic and Cardiovascular Surgafter 100 minutes of hypothermic arrest triggered a marked
loss of myocardial purines from the right ventricle, similar
to that of the left ventricle (Figure E3, A-D).
Cardiac function was depressed in the control group to
about 35% of baseline function. Left ventricle performance
declined to 30.0  7 dyne/cm2$103 and 36.0  6 dyne/
cm2$103 at 30 minutes and 60 minutes reperfusion after car-
dioplegic arrest, respectively (P<.05 vs baseline function,
85.0  3 dyne/cm2$103). In contrast, a significant recovery
of cardiac function was observed the treated group with
EHNA/NBMPR as a hot shot before cold cardioplegia
and was also reperfused with warm blood containing drugs
(Figure 3, A). Recovery of cardiac function at 30 minutes
and 60 minutes of reperfusion after cardioplegic arrestery c October 2013
FIGURE 3. Postischemic inhibition of es-ENT1 abolishes ventricular dysfunction induced by an acute warm aortic crossclamping with or without a period
of 100 minutes of hypothermic cardioplegic arrest. A, Effects of a hot shot and reperfusion with EHNA/NBMPR, before and after continuous retrograde
coronary sinus hypothermic cardioplegia on postischemic recovery of ventricular performance in a canine model of ischemia and reperfusion. The P value
was not significant among groups using analysis of variance. *P<.05 versus baseline and control group. yP<.05 between groups (n ¼ 8). B, Effects of
postischemic reperfusion with EHNA/NBMPR on cardiac functional recovery are summarized in the left and right panels. Left panel, Recovery of heart
performance after normothermic aortic crossclamping and reperfusion with warm blood, without or with EHNA/NBMPR, in the absence of hypothermic
cardioplegic arrest. Preischemic values of ventricular performance in this model of warm ischemia and reperfusion were 103.5  4 dyne/cm2$103 and
101  4 dyne/cm2$103 in the control and EHNA/NBMPR-treated groups, respectively. Right panel, Recovery of heart performance after normothermic
aortic cross-clamping, EHNA/NBMPR hot shot, 100 minutes of continuous retrograde cardioplegia, and reperfusion without and with EHNA/NBMPR.
Preischemic values of ventricular performance in this model of warm ischemia and reperfusion were 85.0  3 dyne/cm2$103 and 76.3  6 dyne/
cm2$103 in the control hot shot and in EHNA/NBMPR hot shot groups, respectively. *P< .05 versus the control group, analysis of variance (n ¼ 8,
each group). EHNA, Erythro-9-[2-hydroxy-3-nonyl] adenine; NBMPR, p-nitro-benzylthioinosine.
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respectively (P-value not significant vs baseline function,
76.3  6 dyne/cm2$103). Figure 3, B summarizes the
efficacy of EHNA/NBMPR intervention in acutely ische-
mic hearts with (Figure 3, B, right panel) or withoutThe Journal of Thoracic and Ca(Figure 3, B, left panel) hypothermic cardioplegic arrest.
Results demonstrated a full recovery of cardiac function
(90%-100%) when ischemic hearts were reperfused with
drugs containing blood without cold cardioplegic arrest.
Significant recovery of left ventricular performancerdiovascular Surgery c Volume 146, Number 4 967
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an EHNA/NBMPR-containing hot shot before hypothermic
cardioplegia and then followed by reperfusion with EHNA/
NBMPR containing blood. Despite recovery of cardiac
function, the levels of myocardial ATP remained depressed
to the levels at the end of 20 minutes of warm ischemia and
were not improved by an additional 100 minutes of hypo-
thermic cardioplegic arrest on-pump. These results demon-
strate that acutely ischemic hearts are well protected during
hypothermic cardioplegic arrest.
DISCUSSION
The rationale of this investigation was that myocardial
purines released from acutely ischemic hearts via the es-
ENT1 nucleoside transporter play a major role in the early
events of reperfusion injury.2,4 Myocardial purines are
considered to be sensitive markers of acute ischemia and
are also known to serve as specific substrates of oxygen-
derived free radicals on reperfusion. Under normothermia,
pharmacologic modulation of purine release from ischemic
myocardium by inhibiting the es-ENT1 nucleoside trans-
porter proved to be an effective strategy in attenuating
purine-mediated reperfusion injury endpoints such as ven-
tricular dysfunction, myocardial stunning,2,13 and
fibrillation.9,18 In the current study, the efficacy of EHNA/
NBMPR in a clinically relevant model has been
challenged with infusion of hypothermic cardioplegia.
Results from this investigation demonstrated that induc-
tion of hypothermic cardioplegia triggers an early release
of (1-4 minutes) of purines from ischemic hearts. However,
purine release stopped completely when the temperature of
the myocardium became cold (<20C) within 2 to 4minutes
induction of cardioplegia (Figure E2, A and B). This obser-
vation was not only noted on the first induction bolus of an-
tegrade cardioplegia (1000 mL), but also was observed with
each consecutive bolus of intermittent antegrade cardiople-
gia (500 mL every 20 minutes). Induction of continuous ret-
rograde coronary sinus hypothermic cardioplegia was also
associated with of release of purines (collected from the aor-
tic cannula) within 1 to 4 minutes, then declined progres-
sively to precardioplegia baseline levels after 4 minutes,
when myocardial temperature reached<20C. Reperfusion
with warm blood triggered total loss of myocardial purines
from cold arrested hearts (Figure 1, A and B, and Table 2) in
both intermittent antegrade and continuous retrograde hypo-
thermic cardioplegia. It was also interesting to note that al-
though early induction of either intermittent or continuous
cold cardioplegia was associated with partial release of pu-
rines in the decanted effluents, the ischemicmyocardium re-
tained most of the inosine and other diffusible purines (total
diffusible purines) during the course of administration (100
minutes) of intermittent antegrade or continuous retrograde
hypothermic cardioplegia (Figure 2, A and B) until reperfu-
sion with warm blood. These observations suggest that968 The Journal of Thoracic and Cardiovascular Surgcellular membranes have lost their ability to diffuse or trans-
port purines when myocardial temperature reaches<20C.
In this respect, there were no differences between intermit-
tent antegrade and continuous retrograde hypothermic car-
dioplegia with respect to entrapment of purine during cold
cardioplegic arrest. Indeed, progressive hypothermia
changes cellular membrane fluidity states from liquid to
gel to solid, during which the membranes become imperme-
able towater and solutes,17 and this may have caused config-
urational changes in membrane-bound proteins and loss of
their physiologic function. It is interesting to note that in
the absence of cold cardioplegia, reperfusion of acutely
ischemic hearts with warm blood containing EHHNA/
NBMPR also inhibited purine loss from the ischemic
myocardium during reperfusion and abolished the ventricu-
lar dysfunction observed in the untreated control group
(Table 3). Considering all our results, specific modulation
of the es-ENT1 nucleoside transporter before or after
warm ischemia, or even with or without prolonged hypo-
thermic cardioplegic arrest, is believed to be an effective
strategy of myocardial protection in experimental models
that simulate the clinical practice of cardiac surgery. How-
ever, it is not known whether inhibition of the es-ENT1 nu-
cleoside transporter by EHNA/NBMPR, per se, provides
other unknownmetabolic mechanisms of protection beyond
that of blockade of purine release and stimulation of free
radical pathways on reperfusion.
Hot Shot Drug Delivery
The rationale for using a hot shot as the delivery system
of EHNA/NBMPR is that cold cardioplegia prevents purine
release as a result of changes in membrane fluidity, and that
drug delivery at normothermia in a depolarized heart would
be more effective than at hypothermia. In the current study,
a terminal hot shot was replaced with warm blood reperfu-
sion with EHNA/NBMPR, without hyperkalemia, at the end
of 20 minutes of warm aortic crossclamping (warm on-
pump surgery) or at the end of 100 minutes of hypothermic
cardioplegic arrest (hypothermic on-pump surgery). Ad-
ministration of a cardioprotective agent as an adjuvant to
cold cardioplegia raises serious questions regarding the ef-
ficiency of drug delivery, doses, and efficacy in clinical tri-
als when hypothermic cardioplegic arrest is used as
a procedure of choice for myocardial protection. Indeed, ex-
perimental studies and clinical trials using adjuvant agents
with hypothermia have overlooked the changes in mem-
brane biophysics, including membrane fluidity and perme-
ability, thus underscoring a drug’s pharmacologic efficacy.
For example, previous experimental studies have demon-
strated that preischemic treatment with low doses of aden-
osine (100 mM or less) exerted powerful cardioprotection
in animal models of acute myocardial infarcation.19 An
early clinical trial with adenosine has demonstrated a lack
of cardioprotective efficacy of adenosine when used as anery c October 2013
Abd-Elfattah et al Evolving Technology/Basic Science
E
T
/B
Sadjuvant drug to hypothermic cardioplegia20 at 5 different
doses between 100 mM and 2 mM. These results demon-
strated that lower requirement of dopamine, but not reduc-
tion in infarct size, was observed in the group of patients
who received the highest dose of adenosine (2 mM)with ad-
ditional preischemic adenosine (140 mg/kg/minute). In
a subsequent trial, 2 doses of adenosine were used (ie,
500 mMand 2mM) along with supplemental adenosine dur-
ing reperfusion of 200 mg adenosine/kg/minute for 10 min-
utes before and 15 minutes after releasing the aortic
crossclamp. The only favorable outcome was a reduced
need for inotropic support as noted in patients who received
only 2 mM adenosine with an additional adenosine supple-
ment.21 Lack of pharmacologic efficacy of adenosine when
used in cold cardioplegia could be related to lack of drug de-
livery resulting from changes in membrane physical proper-
ties.17 Whether adenosine would be more efficacious under
normothermic or tepid temperatures than hypothermic con-
ditions remains to be demonstrated in future clinical trials.
It is anticipated that postischemic warm delivery of
EHNA/NBMPR maximizes pharmacologic efficacy at
normothermia before and after hypothermic cardioplegic
arrest. Introducing EHNA/NBMPR into the cardiopulmo-
nary bypass prior to reperfusion was effective in attenuating
ventricular dysfunction of acutely ischemic hearts under
both normothermic and hypothermic experiments. Results
from the current study suggest that attention should be
paid to manage reperfusion injury not only at reperfusion,
but also during delivery of cardioplegia. Therefore, we are
proposing that warm cardioplegia (hot shot) should be con-
sidered as a means for drug delivery on induction of cardi-
oplegia in addition to that used as terminal warm blood
reperfusion or hot shot after hypothermic cardioplegic ar-
rest in clinical trials.
Pharmacologic intervention with EHNA/NBMPR im-
proved cardiac recovery in a canine model on-pump after
10, 20, 30, and 60 minutes of normothermic aortic cross-
clamping and reperfusion without a period of hypothermic
cardioplegic arrest.2,8,9,13,14 Nevertheless, warm delivery
of EHNA/NBMPR would also be more effective in
clinical cases of off-pump beating heart cardiac surgery
and during intermittent aortic crossclamping without cardi-
oplegic arrest. In this regard, administration of EHNA/
NBMPR before or after myocardial infarction was effective
in attenuating ventricular fibrillation and dysfunction in a ca-
ninemodel of off-pump coronary artery occlusion and reper-
fusion.18 Therefore, myocardial protection for beating heart
cardiac surgery off-pump, in the absence of cardiopulmo-
nary bypass and hypothermic cardioplegic arrest, is feasible.
Nevertheless, EHNA/NBMPRhas been used as a pharmaco-
logic tool to separate the components of ischemic injury
from that of reperfusion injury in a canine model of aortic
crossclamping and reperfusion.3,4 Binding kinetics studies
have demonstrated identification of es-ENT1 binding sitesThe Journal of Thoracic and Cain myocardial preparations of different species, including
humans.22Gene deletion of es-ENT1proved to be protective
in an isolated mouse heart model of ischemia and reperfu-
sion,23 thus supporting our previous2-4,8,9,13-15 and current
findings that the es-ENT1 nucleoside transporter plays ama-
jor role in postischemic reperfusion injury.
Study Limitations
Although the current study demonstrated the efficacy of
EHNA/NBMPR pharmacologic intervention against postis-
chemic reperfusion injury in the settings of warm or cold
cardiac surgery, the long-term survival outcome has not
been addressed in this study and should be considered in fu-
ture clinical trials. The dose of EHNA or NBMPR used in
the current study was not based on a dose/response curve,
but rather was derived from reported Ki values (109 M).
Significant retention of purines in the myocardium of the
EHNA/NBMPR-treated group suggests that doses of both
EHNA and NBMPR were adequate. The issue that is most
important—administration of an EHNA/NBMPR hot shot
at the time of induction of the hot shot or administration
at the time of the reperfusion hot shot—has not been ad-
dressed here but warrants further study. The importance
of timing, temperature, and the route of administration of
cardioprotective drugs must be addressed in clinical trials.
In addition, determining and comparing the effects of cold
and hot shots with without EHNA/NBMPR is important
and should be investigated. Similarly, comparing the effects
of EHNA/NBMPR induction and that of EHNA/NBMPR
hot shot at reperfusion is also warranted. Other concerns
are related to breakdown and metabolism of NBMPR in
the liver and the formation of 6-mercaptopurine. The latter
compound is known to cause adverse effects when given
chronically at high doses in animals.24 In our study, the level
of NBMPR in blood or plasma was found to be below the
sensitivity of HPLC detectors. It is predicted that effects
of a single use of EHNA/NBMPR with low concentrations
would be negligible and might not have long-term effects.
NBMPR is used as a predrug before administration of
nucleoside-derived drugs such as antileukemia and malar-
ial, antiretroviral azidothymidine, and anti-HIV/AIDS
drugs to protect patients’ host cells and, in the meantime,
to reduce their pharmacologic doses.25,26
CONCLUSIONS
In acutely ischemic hearts, induction of intermittent ante-
grade or continuous retrograde hypothermic cardioplegia
promotes partial release of myocardial purines from acutely
ischemic hearts until myocardial temperatures reach
<20C. In contrast, warm blood reperfusion robustly re-
leases purines, causing reperfusion injury. Postischemic re-
perfusion with EHNA/NBMPR abolished myocardial
stunning in the absence of hypothermic cardioplegic arrest.
Postischemic hot shots and reperfusion with EHNA/rdiovascular Surgery c Volume 146, Number 4 969
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SNBMPR also abolished purine-mediated reperfusion injury
following prolonged hypothermic cardioplegic arrest. We
conclude that es-ENT1 plays a major role in postischemic
reperfusion injury in an experimental model simulating in-
traoperative on-pump cardiac surgery in which hypother-
mic cardioplegic arrest is used. Targeting postischemic
reperfusion injury by inhibiting the es-ENT1 nucleoside
transporter is an attractive intervention of intraoperative
myocardial protection, especially in high-risk patients and
redo cardiac surgery.
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2:  Effects of post-ischemic reperfusion with EHNA/NBMPR on myocardial purine levels and left 
ventricular performance in acutely ischemic hearts, without hypothermic cardioplegic arrest
Baseline Ischemia Reperfusion (with Vehicle or EHNA/NBMPR)
Baseline Ischemia Cold Cardioplegia (100 minutes) Reperfusion (with Vehicle or EHNA/NBMPR)
3:  Effects of a hot shot  and reperfusion with EHNA/NBMPR on myocardial purine levels and left 
ventricular performance in acutely ischemic hearts undergoing retrograde hypothermic cardioplegic 
arrest and reperfusion
Hot shot 
Vehicle or EHNA/NBMPR
Intermittent Antegrade
or
Continuous Retrograde
Baseline Ischemia Cold Cardioplegia (100 minutes) Reperfusion
1:  Effects of intermittent antegrade or continuous coronary sinus retrograde hypothermic cardioplegia 
on myocardial purines levels in acutely ischemic hearts 
Continuous Retrograde
Experimental Protocols
FIGURE E1. Experimental protocols. All animals were heparinized, placed on cardiopulmonary bypass, subjected to 20 minutes of normothermic aortic
crossclamping, and divided into the following protocols to determine (1) the effects of intermittent antegrade or continuous coronary sinus retrograde hy-
pothermic cardioplegia on myocardial purine levels in acutely ischemic hearts, (2) the effects of postischemic reperfusion with EHNA/NBMPR on myo-
cardial purine levels and left ventricular performance in acutely ischemic hearts without hypothermic cardioplegic arrest, and (3) the effects of a hot shot and
reperfusion with EHNA/NBMPR on myocardial purine levels and left ventricular performance in acutely ischemic hearts undergoing retrograde hypother-
mic cardioplegic arrest and reperfusion. EHNA, Erythro-9-[2-hydroxy-3-nonyl] adenine; NBMPR, p-nitro-benzylthioinosine.
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FIGURE E2. A, A typical purine release from an acutely ischemic canine
heart (WR 02) during the induction of intermittent antegrade hypothermic
cardioplegia via an aortic cannula and measured in the coronary sinus ef-
fluents is illustrated. Results demonstrate that the first bolus of antegrade
cold cardioplegia was associated with a major release of purines from
the ischemic myocardium into the coronary sinus effluent. Purine release
was abolished when myocardial temperature was<20C. Administration
of each bolus of cardioplegia resulted in a release of purines. Terminal
warm blood reperfusion produced a marked peak of purine release
(Table 2). B, A typical purine release from an acutely ischemic canine heart
(WR 04) during the induction of continuous retrograde coronary sinus hy-
pothermic cardioplegia. Results demonstrated that, while the aortic cross-
clamp was applied, induction with cold retrograde cardioplegia induced
release of purines from the ischemic myocardium into the collected aortic
cannula effluent. The release of purines peaked within a fewminutes of car-
dioplegia and declined during hypothermic arrest. Reperfusion triggered
a massive release of purines collected from the coronary sinus within 10
seconds of reperfusion (Table 2). CPB, Cardiopulmonary bypass.
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FIGURE E3. Effects of a coronary sinus hot shot and reperfusion with
EHNA/NBMPR before and after continuous retrograde coronary sinus hy-
pothermic cardioplegia on myocardial ATP pool metabolism of the right
ventricle in acutely ischemic hearts. All hearts were subjected to 20 min-
utes of warm aortic crossclamping on-pump, a hot shot with or without
EHNA/NBMPR, followed 100 minutes of retrograde hypothermic cardio-
plegic arrest and 60 minutes of reperfusion with or without inhibitors.
*P<.05 versus baseline and the control group; P<.05 between groups
(n ¼ 8). A, Effects of a coronary sinus hot shot and reperfusion with
EHNA/NBMPR before and after continuous retrograde coronary sinus hy-
pothermic cardioplegia on myocardial ATP of the right ventricle in acutely
ischemic hearts. B, Effects of a hot shot and reperfusion with EHNA/
NBMPR before and after continuous retrograde coronary sinus hypother-
mic cardioplegia on myocardial adenosine of the right ventricle in acutely
ischemic hearts. C, Effects of a hot shot and reperfusion with EHNA/
NBMPR, before and after continuous retrograde coronary sinus hypother-
mic cardioplegia on myocardial inosine of the right ventricle in acutely is-
chemic hearts. D, Effects of a hot shot and reperfusion with EHNA/
NBMPR before and after continuous retrograde coronary sinus hypother-
mic cardioplegia on myocardial total diffusible purines
(adenosine + inosine + hypoxanthine + xanthine) of the right ventricle in
acutely ischemic hearts. EHNA, Erythro-9-[2-hydroxy-3-nonyl] adenine;
NBMPR, p-nitro-benzylthioinosine; ATP, adenosine triphosphate; NS, not
significant; ANOVA, analysis of variance; CP, cardioplegia; Rep, reperfu-
sion.
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